Filtered By:
Condition: Heart Disease
Drug: Aspirin

This page shows you your search results in order of date. This is page number 9.

Order by Relevance | Date

Total 179 results found since Jan 2013.

Design and Rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) Trial
Conclusions The EUCLID study is investigating whether treatment with ticagrelor versus clopidogrel, given as antiplatelet monotherapy, will reduce the incidence of cardiovascular and limb-specific events in patients with symptomatic PAD.
Source: American Heart Journal - January 30, 2016 Category: Cardiology Source Type: research

Arguments favoring low versus high dose aspirin in the prophylaxis of venous thromboembolism
The use of aspirin in the prevention of venous thromboembolism (VTE) is still controversial. In a profound review on the use of aspirin for primary and secondary prevention of venous thromboembolism and other cardiovascular disorders Cohen et al. [1] conclude that the benefits of aspirin are well documented for conditions like myocardial infarction, coronary heart disease, and stroke, but less clearly for prevention of VTE after orthopedic surgery. The latter indistinctness has been a matter of concern in many earlier reviews and meta-analyses, and has even led to non-uniform guidelines on VTE prevention from the American ...
Source: Thrombosis Research - January 27, 2016 Category: Hematology Authors: Piet Borgdorff, Geert Jan Tangelder Tags: Correspondence Source Type: research

Longer dual antiplatelet therapy (DAPT) after percutaneous coronary intervention has higher anti-ischaemic efficacy than shorter DAPT but is associated with more frequent bleeding
Commentary on: Spencer FA, Prasad M, Vandvik PO, et al.. Longer- versus shorter-duration dual-antiplatelet therapy after drug-eluting stent placement: a systematic review and meta-analysis. Ann Intern Med 2015;163:118–26. Context Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 receptor antagonist is recommended after drug eluting stent implantation (DES) for at least 12 months by the American College of Cardiology/American Heart Association1 and for 6–12 months by European guidelines. Recent randomised controlled trials (RCT) suggested comparable efficacy of short-term DAPT versus therapy o...
Source: Evidence-Based Medicine - January 22, 2016 Category: Internal Medicine Authors: Navarese, E. P. Tags: Journalology, Clinical trials (epidemiology), Epidemiologic studies, Drugs: cardiovascular system, Stroke, Interventional cardiology, Ischaemic heart disease, Venous thromboembolism, Radiology, Clinical diagnostic tests, Ethics Therapeutics/Prevention Source Type: research

India to join UK for Add-Aspirin global drug trials
Aspirin is widely-used as an analgesic to relieve pain, as well as to manage heart disease and stroke in certain patients.
Source: The Economic Times - January 9, 2016 Category: Consumer Health News Source Type: news

Antithrombotic therapy in patients with combined coronary heart disease and atrial fibrillation.
CONCLUSION: In each clinical scenario, the risks of coronary artery or stent thrombosis in CHD and risks of stroke in AF need to be carefully balanced against the risks of bleeding. We make recommendations for management based on the evidence which is available at this time and indicate the many gaps which are currently being addressed by randomised clinical trials. PMID: 26658287 [PubMed - as supplied by publisher]
Source: Panminerva Medica - December 15, 2015 Category: Journals (General) Tags: Panminerva Med Source Type: research

U.S. task force narrows recommendation for aspirin use
NEW YORK (Reuters) - People between the ages of 50 and 59 years at an increased risk of heart disease and stroke should take daily low-dose aspirin, according to proposed, narrower recommendations from a U.S.-backed panel of independent medical experts.
Source: Reuters: Health - September 14, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

Long-term ticagrelor therapy in patients with prior myocardial infarction significantly reduces ischaemic events, albeit with increased bleeding
Commentary on: Bonaca MP, Bhatt DL, Cohen M, et al., PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791–800. Context Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor antagonist constitute the cornerstone of treatment in patients with acute coronary syndrome (ACS) with a recommended duration of 1 year.1 Nevertheless, high rates of atherothrombotic events, for which platelet activation is heavily implicated, still occur at later stages.2 Therefore, a longer duration of DAPT appears intuitive, a...
Source: Evidence-Based Medicine - July 24, 2015 Category: Internal Medicine Authors: Alexopoulos, D. Tags: Epidemiologic studies, Drugs: cardiovascular system, Stroke, Ischaemic heart disease, Diabetes Therapeutics/Prevention Source Type: research

A Cluster-Randomized Controlled Trial of a Simplified Multifaceted Management Program for Individuals at High Cardiovascular Risk (SimCard Trial) in Rural Tibet, China, and Haryana, India.
CONCLUSIONS: -The results indicate that the simplified cardiovascular management program improved quality of primary care and clinical outcomes in resource-poor settings in China and India. Larger trials in more places are needed to ascertain potential impacts on mortality and morbidity outcomes. Clinical Trial Registration Information-clinicaltrials.gov. Identifier: NCT01503814. PMID: 26187183 [PubMed - as supplied by publisher]
Source: Circulation - July 17, 2015 Category: Cardiology Authors: Tian M, Ajay V, Dunzhu D, Hameed S, Li X, Liu Z, Li C, Chen H, Cho K, Li R, Zhao X, Jindal D, Rawal I, Ali MK, Peterson ED, Ji J, Amarchand R, Krishnan A, Tandon N, Xu LQ, Wu Y, Prabhakaran D, Yan L Tags: Circulation Source Type: research

FDA strengthens warning that NSAIDs increase heart attack and stroke risk
Back in 2005, the FDA warned that taking nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen increased the risk of having a heart attack or stroke. Last week it took the unusual step of further strengthening this warning. This was done on the advice of an expert panel that reviewed new information about NSAIDs and their risks. Because NSAIDs are widely used, it’s important to be aware of downsides of taking an NSAID and to take steps to limit the risk. Many people take NSAIDs to relieve mild to moderate pain. These medications may be particularly effective in conditions in which pain results pri...
Source: New Harvard Health Information - July 13, 2015 Category: Consumer Health News Authors: Gregory Curfman, MD Tags: Heart Health heart attack heart disease NSAIDS Stroke Source Type: news

Antiplatelet therapy following transcatheter aortic valve implantation
Conclusions No difference in 30-day NACE rate was observed between ASA-only or DAPT following TAVI. Moreover, a trend towards less life-threatening and major bleeding was observed in favour of ASA. Consequently the additive value of clopidogrel warrants further investigation.
Source: Heart - June 25, 2015 Category: Cardiology Authors: Hassell, M. E. C. J., Hildick-Smith, D., Durand, E., Kikkert, W. J., Wiegerinck, E. M. A., Stabile, E., Ussia, G. P., Sharma, S., Baan, J., Eltchaninoff, H., Rubino, P., Barbanti, M., Tamburino, C., Poliacikova, P., Blanchard, D., Piek, J. J., Delewi, R. Tags: Drugs: cardiovascular system, Epidemiology Valvular heart disease Source Type: research

Two-year clinical outcome from the Iberian registry patients after left atrial appendage closure
Conclusions LAA closure with an occlusion device in patients contraindicated for oral anticoagulants is a therapeutic option associated with fewer thromboembolic and haemorrhagic events than expected from risk scores, particularly in the second year postimplantation.
Source: Heart - May 12, 2015 Category: Cardiology Authors: Minguez, J. R. L., Asensio, J. M. N., Gragera, J. E., Costa, M., Gonzalez, I. C., de Carlos, F. G., Diaz, J. A. F., Yuste, V. M., Gonzalez, R. M., Dominguez-Franco, A., Buendia, A. B., Garibi, J. H., Hernandez, F. H., Ribeiro, V. G. Tags: Congenital heart disease in adult patients, Editor's choice, Drugs: cardiovascular system, Heart failure, Hypertension, Epidemiology Arrhythmias and sudden death Source Type: research

Prevalence and antithrombotic management of atrial fibrillation in hospitalised patients
Conclusions This hospital-based study revealed high AF prevalence rates (16.8%). Patients with AF were present in all hospital zones and almost all patients were at high risk for stroke. Anticoagulation management was likely inappropriate in 48.7%, indicating the need for better guideline implementation initiatives to guarantee hospital-wide optimised care for patients with AF.
Source: Heart - May 12, 2015 Category: Cardiology Authors: Berti, D., Moors, E., Moons, P., Heidbuchel, H. Tags: Drugs: cardiovascular system, Hypertension Arrhythmias and sudden death Source Type: research

Aspirin in the perioperative period: a review of the recent literature
Purpose of review: The indications for aspirin (ASA) for both primary and secondary prevention of thrombotic events continue to evolve. We review some of these indications and the recent literature regarding the perioperative administration of ASA. Recent findings: ASA for primary prevention of cardiac ischemia, stroke, cancer, and death remains controversial. When used for primary prevention, ASA may be safely discontinued perioperatively. Patients with coronary or carotid artery stents should continue to receive ASA perioperatively. For patients with ischemic heart disease currently receiving ASA for secondary prevention...
Source: Current Opinion in Anaesthesiology - May 1, 2015 Category: Anesthesiology Tags: ANESTHESIA AND MEDICAL DISEASE: Edited by Natalie F. Holt Source Type: research

Premature Ventricular Complexes on Screening Electrocardiogram and Risk of Ischemic Stroke Brief Reports
Conclusions— PVCs are common on routine screening ECGs and are associated with an increased risk of ischemic stroke.
Source: Stroke - April 27, 2015 Category: Neurology Authors: Agarwal, S. K., Chao, J., Peace, F., Judd, S. E., Kissela, B., Kleindorfer, D., Howard, V. J., Howard, G., Soliman, E. Z. Tags: Electrocardiology, Embolic stroke, Epidemiology Brief Reports Source Type: research

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States Coronary Heart Disease
Conclusions In patients with prior MI or PAD who have not had a previous stroke or TIA, vorapaxar added to standard therapy is effective for long-term secondary prevention of thrombotic CV events, while increasing moderate or severe bleeding. Clinical Trial Registration URL: clinicaltrials.gov Unique Identifier: NCT00526474.
Source: JAHA:Journal of the American Heart Association - March 19, 2015 Category: Cardiology Authors: Magnani, G., Bonaca, M. P., Braunwald, E., Dalby, A. J., Fox, K. A. A., Murphy, S. A., Nicolau, J. C., Oude Ophuis, T., Scirica, B. M., Spinar, J., Theroux, P., Morrow, D. A. Tags: Coronary Heart Disease Source Type: research